Dolutegravir monotherapy in HIV-1-suppressed patients: A feasible regimen in real life. 2018

Emanuela Lattuada, and Massimiliano Lanzafame, and Stefano Nicolè, and Fabio Rigo, and Giulia Cucchetto, and Ercole Concia, and Sandro Vento
1 Infectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010078 Oxazines Six-membered heterocycles containing an oxygen and a nitrogen.
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011728 Pyridones Pyridine derivatives with one or more keto groups on the ring. Pyridinones
D006575 Heterocyclic Compounds, 3-Ring A class of heterocyclic compounds that include a three-ring fused structure. Both aromatic or non-aromatic ring structures are included in this category. Fused Heterocyclic Compounds, Three-Ring,Heterocyclic Cpds, 3 Ring,Three Ring Heterocyclic Compounds,3-Ring Heterocyclic Compounds,Fused Heterocyclic Compounds, Three Ring,Heterocyclic Compounds, 3 Ring
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072230 Sustained Virologic Response The continuous, long-term suppression of VIRAL LOAD, generally to undetectable levels, as the result of treatment with ANTIVIRAL AGENTS. Sustained Viral Suppression,Response, Sustained Virologic,Suppression, Sustained Viral,Sustained Viral Suppressions,Sustained Virologic Responses,Virologic Response, Sustained
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA

Related Publications

Emanuela Lattuada, and Massimiliano Lanzafame, and Stefano Nicolè, and Fabio Rigo, and Giulia Cucchetto, and Ercole Concia, and Sandro Vento
September 2016, The Journal of antimicrobial chemotherapy,
Emanuela Lattuada, and Massimiliano Lanzafame, and Stefano Nicolè, and Fabio Rigo, and Giulia Cucchetto, and Ercole Concia, and Sandro Vento
September 2016, The Journal of antimicrobial chemotherapy,
Emanuela Lattuada, and Massimiliano Lanzafame, and Stefano Nicolè, and Fabio Rigo, and Giulia Cucchetto, and Ercole Concia, and Sandro Vento
April 2019, HIV research & clinical practice,
Emanuela Lattuada, and Massimiliano Lanzafame, and Stefano Nicolè, and Fabio Rigo, and Giulia Cucchetto, and Ercole Concia, and Sandro Vento
June 2016, The Journal of antimicrobial chemotherapy,
Emanuela Lattuada, and Massimiliano Lanzafame, and Stefano Nicolè, and Fabio Rigo, and Giulia Cucchetto, and Ercole Concia, and Sandro Vento
July 2020, The Annals of pharmacotherapy,
Emanuela Lattuada, and Massimiliano Lanzafame, and Stefano Nicolè, and Fabio Rigo, and Giulia Cucchetto, and Ercole Concia, and Sandro Vento
March 2022, Viruses,
Emanuela Lattuada, and Massimiliano Lanzafame, and Stefano Nicolè, and Fabio Rigo, and Giulia Cucchetto, and Ercole Concia, and Sandro Vento
January 2020, Drugs,
Emanuela Lattuada, and Massimiliano Lanzafame, and Stefano Nicolè, and Fabio Rigo, and Giulia Cucchetto, and Ercole Concia, and Sandro Vento
July 2018, The Journal of infectious diseases,
Emanuela Lattuada, and Massimiliano Lanzafame, and Stefano Nicolè, and Fabio Rigo, and Giulia Cucchetto, and Ercole Concia, and Sandro Vento
April 2022, The Annals of pharmacotherapy,
Emanuela Lattuada, and Massimiliano Lanzafame, and Stefano Nicolè, and Fabio Rigo, and Giulia Cucchetto, and Ercole Concia, and Sandro Vento
March 2017, BMC infectious diseases,
Copied contents to your clipboard!